Literature DB >> 28273769

Infection-related health care utilization among people with and without multiple sclerosis.

José Ma Wijnands1, Elaine Kingwell1, Feng Zhu1, Yinshan Zhao1, John D Fisk2, Charity Evans3, Ruth Ann Marrie4, Helen Tremlett1.   

Abstract

BACKGROUND: Little is known about infection risk in multiple sclerosis (MS).
OBJECTIVE: We examined infection-related health care utilization in people with and without MS.
METHODS: Using population-based health administrative data from British Columbia, Canada, people with MS were followed from their first demyelinating claim (1996-2013) until death, emigration, or study end (2013). Infection-related hospital, physician, and prescription data of MS cases were compared with sex-, age-, and geographically matched controls using adjusted regression models. Sex and age differences (18-39, 40-49, 50-59, 60+ years) were explored.
RESULTS: Relative to 35,837 controls, 7179 MS cases were over twice as likely to be hospitalized for infection (adjusted odds ratio: 2.39; 95% confidence interval (CI): 2.16-2.65), had 41% more physician visits (adjusted rate ratio (aRR): 1.41; 95% CI: 1.36-1.47), and filled 57% more infection-related prescriptions (aRR: 1.57; 95% CI: 1.49-1.65). Utilization was disproportionately higher in MS men than women and was elevated across all ages. MS cases had nearly twice as many physician visits and two to three times more hospitalizations for pneumonia, urinary system infections, and skin infections (aRRs ranged from 1.6 to 3.3) and over twice as many hospitalizations for intestinal infections (aRR = 2.6) and sepsis (aRR = 2.2).
CONCLUSION: Infection-related health care utilization was increased in people with MS across all age groups, with a higher burden for men.

Entities:  

Keywords:  Multiple sclerosis; health care utilization; infections; population-based data

Mesh:

Year:  2016        PMID: 28273769     DOI: 10.1177/1352458516681198

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  32 in total

1.  Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD.

Authors:  Sara Esmaeili; Mohammad Hossein Abbasi; Meysam Abolmaali; Mohammad Mojtahed; Seyedeh Niloufar Rafiei Alavi; Sevim Soleimani; Mahisa Mokhtari; Jaber Hatam; Samaneh Tanhapour Khotbehsara; Mohammad Reza Motamed; Mohammad Taghi Joghataei; Zahra Mirzaasgari; Mehdi Moghaddasi
Journal:  BMC Neurol       Date:  2021-05-01       Impact factor: 2.474

2.  Measurement of mucociliary clearance in the patients with multiple sclerosis.

Authors:  Ender Sahin; Mehmet Hamamcı; Yunus Kantekin
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-11-09       Impact factor: 2.503

Review 3.  SARS-CoV-2 (COVID-19) in Patients with some Degree of Immunosuppression.

Authors:  Jairo Cajamarca-Baron; Diana Guavita-Navarro; Jhon Buitrago-Bohorquez; Laura Gallego-Cardona; Angela Navas; Hector Cubides; Ana María Arredondo; Alejandro Escobar; Adriana Rojas-Villarraga
Journal:  Reumatol Clin (Engl Ed)       Date:  2020-09-11

4.  Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times?

Authors:  Francesco Ferrara; Raffaele La Porta; Priscilla Santilli; Vilma D'Aiuto; Antonio Vitiello
Journal:  Indian J Pharmacol       Date:  2020 Sep-Oct       Impact factor: 1.200

5.  B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with Multiple Sclerosis during the early COVID-19 epidemic in Iran.

Authors:  Farinaz Safavi; Bardia Nourbakhsh; Amir Reza Azimi
Journal:  Mult Scler Relat Disord       Date:  2020-05-13       Impact factor: 4.339

6.  Uptake and Attitudes About Immunizations in People With Multiple Sclerosis.

Authors:  Ruth Ann Marrie; Leanne Kosowan; Gary R Cutter; Robert Fox; Amber Salter
Journal:  Neurol Clin Pract       Date:  2021-08

7.  Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis.

Authors:  Ruth Ann Marrie; Casandra Dolovich; Gary R Cutter; Robert J Fox; Amber Salter
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-05-22

8.  Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study.

Authors:  Martin S Weber; Mathias Buttmann; Sven G Meuth; Petra Dirks; Erwan Muros-Le Rouzic; Julius C Eggebrecht; Stefanie Hieke-Schulz; Jost Leemhuis; Tjalf Ziemssen
Journal:  Front Neurol       Date:  2022-05-09       Impact factor: 4.086

9.  Multiple Sclerosis at Home Access (MAHA): An Initiative to Improve Care in the Community.

Authors:  Kathleen Healey; Rana Zabad; Lufei Young; Aubrie Lindner; Nancy Lenz; Renee Stewart; Mary Charlton
Journal:  Int J MS Care       Date:  2019 May-Jun

Review 10.  Sepsis and multiple sclerosis: Causative links and outcomes.

Authors:  Đorđe Miljković; Suzana Stanisavljević; Isaac J Jensen; Thomas S Griffith; Vladimir P Badovinac
Journal:  Immunol Lett       Date:  2021-07-25       Impact factor: 4.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.